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Objective. The genes for killer-cell immunoglobulin-like receptors (KIRs) have been cloned and their functions and expression
in patients with rheumatoid arthritis (RA) have been partially clariﬁed. However, the correlation between their expression and
disease activity has not been analyzed in patients with RA. Thus, we measured KIR expression on lymphocytes in patients with
RA, and assessed the correlation between KIR expression and disease activity. Patients and Methods. In the cross-sectional study,
15 patients (9 females and 6 males) who fulﬁlled the diagnostic criteria for RA were assessed. In the longitudinal study, patients
who were followed-up for 3 months were assessed. CD158a/b expression on peripheral blood mononuclear cells (PBMC) of RA
patients was analyzed using ﬂow cytometry. Results. No signiﬁcant correlation between KIR expression and CRP, ESR, or IgM-RF
was observed. There was no remarkable change in the expression of KIRs between the baseline and after 3 months. Additionally, in
the 5 patients whose expression of KIRs particularly changed, the time-related changes in the expression of KIRs were independent
from those of inﬂammation parameters and IgM-RF. Conclusion. There was no correlation between KIR expression and disease
activity; therefore, the clinical use of KIR expression should be limited, while unnatural KIR expression may be involved in the
pathogenesis of RA, but not a recruitment of chronic inﬂammation to induce joint damage.
Copyright © 2007 Toshiaki Kogure et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
ThemolecularcloningofnovelNKreceptors(NKRs)wasre-
ported [1–3], and it was subsequently shown that the recep-
tors transmit negative signals [4, 5]. In human, NKRs can be
divided into 3 classes: immunoglobulin (Ig)-like receptors,
including killer cell Ig-like receptors (KIRs) and leukocyte
Ig-like receptors (LIRs), lectine-like receptors (CD94/NKG),
andnaturalcytotoxicityreceptors(NCRs),includingNKp30,
NKp44, and NKp46 [6].
KIRs are expressed on many NK cells and on subpopula-
tionsofT-cells[7],andhavebeenimplicatedinautoimmune
conditions such as rheumatoid arthritis (RA) [8, 9] and scle-
roderma [10], where associations have been found with 3-
domain KIRs (KIR2DL1, 2, and 3) known to recognize HLA-
Ca l l e l e s[ 11, 12]. We have also demonstrated that the ex-
pression of KIR2DL1 on CD8+ T cells was reduced in pa-
tients with RA compared to healthy subjects, and that the
upregulation of KIR2DL1, 2, and 3 by treatment with IL-2
w a sw e a k e ri nR Ap a t i e n t st h a ni nh e a l t h ys u b j e c t s[ 9]. Low
KIR expression on CD8+ T cells in RA might be associated
with the mechanism of self-attacking characteristics of au-
toimmune diseases. Also, the low response of KIRs to IL-2
suggests that patients with RA might be highly susceptible2 Mediators of Inﬂammation
to Mycobacterium tuberculosis (TB). Based on these ﬁndings,
it is considered that the status of KIR expression may be in-
volved in the pathogenesis of RA as well as susceptibility to
microbes such as TB [13].
RA is a chronic destructive joint disease and a heteroge-
neous syndrome. Therefore, the disturbance of KIR expres-
sion in RA raises an interesting question: does KIR expres-
sion on peripheral lymphocytes in patients with RA change
with disease activity or not? However, changes in KIR ex-
pression on lymphocytes have not yet been analyzed in RA
patients.
Here, we measured KIR expression on lymphocytes in
patients with RA, and assessed the correlation between KIR
expression and disease activity and changes in KIR expres-
sion during the disease course.
2. PATIENTS AND METHODS
2.1. Patients
Fifteen patients (9 females and 6 males) with ﬂares of RA as
deﬁned by the revised criteria of the American College of
Rheumatology [14] were included in this study. The char-
acteristics of these patients were as follows: mean ± SD
age of 62.0 ± 9.4 years (range: 42–72), mean ± SD dis-
ease duration of 8.1 ± 6.2 years (range: 2–24), mean ± SD
ESR (erythrocyte sedimentation rate) 48 ± 35mm/h (range:
28–86), mean ± SD CH50 (serum complement titer/50%
hemolytic unit of complement) 36.9 ± 7.0U/mL (range: 28–
52), anatomical stage [15]2 .2 ± 1.4, and functional class
2.1 ± 0.5. All were receiving nonsteroidal anti-inﬂammatory
drugs (NSAIDs). Two were also taking Bucillamine, 7 Sala-
zosulfapyridine, and 4 Prednisolone (PSL, 2.5–7.5mg/day).
Eight patients were receiving Methotrexate. No patient was
receiving Inﬂiximab.
2.2. Reagentsandcells
Fluorescein-isothiocyanate (FITC)-conjugated antihuman
CD16, phycoerythrin (PE)-conjugated antihuman CD158a
(EB6),andPE-conjugatedantihumanCD158b(GL183)were
purchased from Immunotech, Marseille, France. Antibody
EB6 reacts with KIR2DL1 and KIR2DS1, and GL183 reacts
with KIR2DL2, KIR2DL3, and KIR2DS2 [11, 12].
Peripheral blood mononuclear cells (PBMCs) obtained
from patients with RA were separated from heparinized
blood by Lymphoprep (Nyegaard, Oslo, Norway) gradient
centrifugation [16]. Each PBMC was incubated in a cul-
ture dish in a humidiﬁed 5% CO2/95% air atmosphere at
37◦C for 60 minutes. After incubation, nonadherent cells
were collected. These cell suspensions were washed twice in
phosphate-buﬀered saline (PBS).
2.3. Cellphenotype
Surface phenotyping was carried out using a two-color im-
munoﬂuorescence staining technique, with isotype-speciﬁc
mouse antihuman antibody conjugated with either FITC
or PE [17]. Each sample of stained cells was suspended in
0.5mL of PBS and analyzed by ﬂow cytometry. Lymphocyte
subsets were identiﬁed by gating analysis, and ﬂuorescence
proﬁles were obtained for 10000 cells from each sample.
Negative controls for each experiment were performed with
FITC- and PE-labeled mouse immunoglobulin-G (Ig-G).
2.4. Statisticalanalysis
Data are expressed as mean (SD) values. All data were
collected in a computer database and analyzed using the
StatView-J 4.02 program (Abacus Concept, Berkeley, Calif,
USA). The Mann-Whitney u test was performed for each set
of the surface antigen. For all statistical tests, diﬀerences were
regarded as signiﬁcant if P<. 05.
3. RESULTS
The correlation between the counts of KIR-expressing cells
and disease activity in RA.
The correlation between CD158a/b-expressing cells and
CRP, ESR, and IgM-rheumatoid factor (IgM-RF) is sum-
marized in Table 1. There was no correlation between the
counts of CD158a-expressing cells and disease activity, al-
though there was a tendency towards a correlation be-
tween CD158a-expressing cells and ESR. Also, the counts of
CD158b-expressing cells did not correlate with classical in-
ﬂammatory parameters (CRP: C-reactive protein, and ESR)
and IgM-RF.
The changes of CD158a- and CD158b-expressing cells
during the followup of 3 months.
Figure 1 shows the changes in the populations of cells
expressing CD158a (Figure 1(a)) and CD158b (Figure 1(b))
during the followup of 3 months. Ten of the RA patients
did not show changes in the expression of CD158a and
CD158b. Two patients showed an expansion of the popu-
lations of both CD158a- and CD158b-expressing cells. In
contrast, 3 patients showed decrease in the populations of
both CD158a- and CD158b-expressing cells. However, time-
relatedchangesintheexpressionofCD158a/bwereindepen-
dent from those of inﬂammation parameters and IgM-RF in
the 5 cases (Figure 1). Additionally, there were no diﬀerences
in clinical features among the three groups: (i) patients with
no changes in KIR expression, (ii) patients with a decrease
in KIR expression, and (iii) patients with an increase in KIR
expression (data not shown).
4. DISCUSSION
The biological functions of KIRs have been thoroughly
investigated. In brief, NK cell function is generally reg-
ulated by a balance between signals transmitted by in-
hibitory and stimulatory receptors. Ligand binding to in-
hibitory receptors recruits phosphatases that dephospho-
rylate downstream activation proteins, thereby terminating
the activating-signaling pathway. Thus, activation of NK cell
functionoccurswhenthereisanetexcessofstimulatoryover
inhibitory signals [18].Toshiaki Kogure et al. 3
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Figure 1: Changes in the counts of CD158a- and CD158b-expressing cells during the followup of 3 months: (a) CD158a cells and (b)
CD158b cells. The majority of RA patients did not show changes in the numbers of CD158a- and CD158b-expressing cells. Five patients (•)
underwent an expansion or reduction in the populations of both CD158a- and CD158b-expressing cells. However, time-related changes in
the expression of CD158a/b were independent from those of inﬂammation parameters and IgM-RF in the 5 cases.
Table 1: The correlation between the counts of KIRs-expressing
cells and disease activity in RA.
CD158a Probability Spearman’s rank
correlation coeﬃcient
CRP∗ 0.386 0.241
ESR∗∗ 0.052 0.517
IgM-RF# 0.411 0.239
CD158b Probability Spearman’s rank
correlation coeﬃcient
CRP 0.991 0.003
ESR 0.651 0.127
IgM-RF 0.939 0.023
∗CRP: C-reactive protein.
∗∗ESR: erythrocyte sedimentation rate.
#IgM-RF: IgM-rheumatoid factor.
Recent studies have demonstrated ﬁndings supporting
theimportantfunctionsofNKcellsinregulatingautoimmu-
nity [19]. We have also demonstrated that the population of
CD8+CD158a+ cells was reduced in patients with RA com-
pared to healthy subjects [9]. Similarly, Nakiri et al. have re-
ported that among patients with RA, NKB1+CD8+ T cells
decreased signiﬁcantly in comparison to controls [20]. It
is considered that the low population of KIR-expressing
cells in T cells might be associated with the mechanism of
self-attacking characteristics of autoimmune diseases, and
that an unnatural expression of KIRs may contribute to the
pathogenesis of RA. However, it has not been demonstrated
whether KIR expression correlates with disease activity in
RA.
As far as we know, this is the ﬁrst report to assess the
correlation between KIR expression and disease activity. In
this study, we did not ﬁnd a signiﬁcant relationship be-
tweenCD158a/bexpressiononperipherallymphocytes,clas-
sical inﬂammatory parameters (CRP and ESR), and IgM-RF.
These ﬁndings suggest that unnatural KIR expression con-
tributes to one of the triggers of RA pathogenesis, but not
a recruitment of chronic inﬂammation to induce joint dam-
age.Other investigators have revealed that the KIR2DS2 gene
was signiﬁcantly enriched among patients with vasculitis in
RA [8].
Furthermore, we have observed the changes in the popu-
lation of CD158a/b-expressing cells. In this followup, time-
related changes in the population of KIR-expressing cells
were independent from those of inﬂammation parameters
and IgM-RF. Additionally, the patients were divided into 3
groups according to the pattern of changes in the population
of KIR-expressing cells. However, there was no diﬀerence in
the clinical features among the 3 groups: (i) patients with no
changes in KIR expression, (ii) patients with a decrease in
KIR expression, and (iii) patients with an increase in KIR ex-
pression. We also did not ﬁnd any correlation in the disease
activitybetweenthese3groups.Theseﬁndingsmayalsosug-
gest that unnatural KIR expression contributes to one of the
triggers of RA pathogenesis, but not a recruitment of chronic
inﬂammation to induce joint damage. To support this hy-
pothesis, further analysis of KIR expression on the cells of
several lineages is required.
Finally, there was no correlation between KIR expression
and disease activity; therefore, the clinical use of KIR expres-
sion should be limited, while unnatural KIR expression may
be involved in the pathogenesis of RA, but not a recruitment
of chronic inﬂammation to induce joint damage.4 Mediators of Inﬂammation
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